ENJUVIA (estrogens, conjugated synthetic b) by Aspen Surgical is clinical pharmacology endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Approved for the: treatment of moderate to severe vasomotor symptoms associated with menopause. First approved in 2004.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
ENJUVIA is an oral tablet containing conjugated synthetic estrogens, B approved for treatment of moderate to severe vasomotor symptoms associated with menopause. The drug works by binding to nuclear estrogen receptors to modulate gonadotropin secretion and reduce elevated LH and FSH levels in postmenopausal women. It utilizes a slow-release formulation that provides sustained absorption over several hours.
Product approaching loss of exclusivity with moderate competitive pressure (30); expect brand team contraction and focus shift toward cost management and patient retention.
CLINICAL PHARMACOLOGY Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal…
Worked on ENJUVIA at Aspen Surgical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Clinical Trial to Evaluate the Safety and Efficacy of Enjuvia 0.3 mg for the Treatment of Vulvovaginal Atrophy
Aspen Surgical is hiring 1 role related to this product
With zero linked job openings and LOE approaching, career opportunities on ENJUVIA are limited and declining. Roles available focus on defending market share and managing transition to generic competition rather than growth initiatives.